Início › Linfoma folicular › Massachusetts › Boston
Ensaios clínicos de Linfoma folicular em Boston, MA
17 estudos para Linfoma folicular estão buscando participantes em locais em Boston e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecrutandoFase 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecrutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
RecrutandoFase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecrutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecrutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecrutandoFase 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
RecrutandoFase 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RecrutandoFase 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecrutandoFase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RecrutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RecrutandoFase 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RecrutandoFase 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
RecrutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RecrutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
RecrutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
RecrutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RecrutandoFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ensaios de Linfoma folicular em outras cidades
- New York City, NY24 estudos
- Milwaukee, WI19 estudos
- Nashville, TN18 estudos
- Houston, TX18 estudos
- Baldwin Park, CA16 estudos
- Seattle, WA15 estudos
- Durham, NC15 estudos
- Columbus, OH13 estudos
- Salt Lake City, UT13 estudos
- San Antonio, TX12 estudos
- Chicago, IL12 estudos
- Philadelphia, PA12 estudos
Outros estudos em Boston
- Câncer de Mama111 estudos
- Câncer de Pulmão de Não Pequenas Células90 estudos
- Câncer (todos os tipos)86 estudos
- Câncer Colorretal63 estudos
- Câncer Metastático63 estudos
- Câncer de Pulmão62 estudos
- Câncer de Ovário61 estudos
- Câncer de Próstata59 estudos
- Depressão52 estudos
- Câncer Endometrial50 estudos
- Insuficiência Cardíaca44 estudos
- Leucemia Mieloide Aguda44 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.